Leussink, Berend T;
Baelde, Hans J;
den Berg, Thirza M Broekhuizen-van;
de Heer, Emile;
van der Voet, Gijsbert B;
Slikkerveer, Anja;
Bruijn, Jan A;
de Wolff, Frederik A
Renal epithelial gene expression profile and bismuth-induced resistance against cisplatin nephrotoxicity
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Renal epithelial gene expression profile and bismuth-induced resistance against cisplatin nephrotoxicity
Contributor:
Leussink, Berend T;
Baelde, Hans J;
den Berg, Thirza M Broekhuizen-van;
de Heer, Emile;
van der Voet, Gijsbert B;
Slikkerveer, Anja;
Bruijn, Jan A;
de Wolff, Frederik A
Published:
SAGE Publications, 2003
Published in:
Human & Experimental Toxicology, 22 (2003) 10, Seite 535-540
Language:
English
DOI:
10.1191/0960327103ht393oa
ISSN:
0960-3271;
1477-0903
Origination:
Footnote:
Description:
Nephrotoxicity is the most important dose-limiting factor in cisplatin based anti-neoplastic treatment. Pretreatment with bismuth salts, used as pharmaceuticals to treat gastric disorders, has been demonstrated to reduce cisplatin-induced renal cell death in clinical settings and during in vivo and in vitro animal experiments. To investigate the genomic basis of this renoprotective effect, we exposed NRK-52E cells, a cell line of rat proximal tubular epithelial origin, to 33 mM Bi3for 12 hours, which made them resistant to cisplatin-induced apoptosis. Differentially expressed genes in treated and untreated NRK-52E cells were detected by subtraction PCR and microarray techniques. Genes found to be down regulated (0.17/0.31-times) were cytochrome c oxidase subunit I, BAR (an apoptosis regulator), heat-shock protein 70-like protein, and three proteins belonging to the translation machinery (ribosomal proteins S7 and L17, and S1, a member of the elongation factor 1-alpha family). The only up-regulated gene was glutathione Stransferase subunit 3A (1.89-times). Guided by the expression levels of these genes, it may be possible to improve renoprotective treatments during anti-neoplastic therapies.